Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Needham Maintains Buy on Equifax, Raises Price Target to $260

Needham analyst Kyle Peterson maintains Equifax (NYSE:EFX) with a Buy and raises the price target from $215 to $260.

byBenzinga Newsdesk

April 22, 2021

1 minute read

Needham analyst Kyle Peterson maintains Equifax (NYSE:EFX) with a Buy and raises the price target from $215 to $260.

Morgan Stanley Downgrades Sterling Check to Equal-Weight, Announces $26 Price Target

By Benzinga Newsdesk

Today, 3:12 AM

Morgan Stanley analyst Toni Kaplan downgrades Sterling Check (NASDAQ:STER) from Overweight to Equal-Weight and announces $26 price target.

STER

Needham Reiterates Buy on Bicycle Therapeutics, Maintains $72 Price Target

By Benzinga Newsdesk

Today, 3:12 AM

Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.

BCYC

Fiverr International Sees Q4 Revenue Of $79.8M-$85.8M vs $83.99M Est; FY22 Revenue Of $334M-$340M vs $336.86M

By Benzinga Newsdesk

Today, 3:12 AM

Financial Outlook Our Q4'22 outlook and full year 2022 guidance reflects the recent trends on our marketplace and is largely consistent with our prior

FVRR

Alpha Tau Announces Completion Of Enrollment Of Japanese Pivotal Clinical Trial In Recurrent Head & Neck Cancer

By Benzinga Newsdesk

Today, 3:12 AM

Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner

HCCC

Needham Maintains Buy on Equifax, Raises Price Target to $260

Related Posts

Morgan Stanley Downgrades Sterling Check to Equal-Weight, Announces $26 Price Target

Needham Reiterates Buy on Bicycle Therapeutics, Maintains $72 Price Target

Fiverr International Sees Q4 Revenue Of $79.8M-$85.8M vs $83.99M Est; FY22 Revenue Of $334M-$340M vs $336.86M

Alpha Tau Announces Completion Of Enrollment Of Japanese Pivotal Clinical Trial In Recurrent Head & Neck Cancer